Short Interest in Vicarious Surgical Inc. (NYSE:RBOT) Declines By 31.2%

Vicarious Surgical Inc. (NYSE:RBOT) was the target of a large decline in short interest during the month of February. As of February 27th, there was short interest totaling 264,129 shares, a decline of 31.2% from the February 12th total of 383,672 shares. Based on an average daily trading volume, of 76,584 shares, the days-to-cover ratio is currently 3.4 days. Currently, 4.5% of the shares of the company are short sold. Currently, 4.5% of the shares of the company are short sold. Based on an average daily trading volume, of 76,584 shares, the days-to-cover ratio is currently 3.4 days.

Analyst Upgrades and Downgrades

Several research firms have issued reports on RBOT. Weiss Ratings restated a “sell (e+)” rating on shares of Vicarious Surgical in a research note on Wednesday, January 21st. Wall Street Zen cut shares of Vicarious Surgical from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Finally, BTIG Research restated a “neutral” rating on shares of Vicarious Surgical in a research report on Friday, December 12th. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus target price of $7.00.

Vicarious Surgical Price Performance

Shares of RBOT opened at $0.54 on Monday. The firm has a market capitalization of $3.54 million, a P/E ratio of -0.06 and a beta of 1.53. Vicarious Surgical has a one year low of $0.27 and a one year high of $13.75. The business has a fifty day moving average of $1.98 and a 200 day moving average of $3.59.

Vicarious Surgical (NYSE:RBOT) last posted its earnings results on Monday, March 9th. The company reported ($1.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.37) by ($0.28). Analysts expect that Vicarious Surgical will post -10.89 EPS for the current fiscal year.

Hedge Funds Weigh In On Vicarious Surgical

A number of institutional investors and hedge funds have recently made changes to their positions in the business. DNB Asset Management AS grew its position in Vicarious Surgical by 12.1% during the second quarter. DNB Asset Management AS now owns 29,199 shares of the company’s stock valued at $219,000 after buying an additional 3,154 shares during the period. Dimensional Fund Advisors LP raised its position in Vicarious Surgical by 22.1% in the third quarter. Dimensional Fund Advisors LP now owns 19,975 shares of the company’s stock worth $110,000 after acquiring an additional 3,615 shares during the period. Connective Capital Management LLC bought a new position in Vicarious Surgical in the third quarter worth approximately $169,000. Geode Capital Management LLC boosted its stake in shares of Vicarious Surgical by 26.0% during the 4th quarter. Geode Capital Management LLC now owns 40,494 shares of the company’s stock worth $88,000 after acquiring an additional 8,344 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Vicarious Surgical during the 4th quarter valued at $98,000. Hedge funds and other institutional investors own 47.27% of the company’s stock.

Vicarious Surgical Company Profile

Vicarious Surgical develops a next-generation robotic surgical system that integrates virtual reality (VR) with minimally invasive instrumentation. Its flagship offering combines ultra-slender, articulated robotic arms with a VR surgeon console, allowing physicians to perform laparoscopic procedures with enhanced precision, dexterity and visual immersion. The platform is designed to reduce patient trauma compared with traditional open or laparoscopic surgery and to expand surgeon access to challenging operative sites.

The company’s technology is intended for use across multiple surgical specialties, including general surgery, gynecology and urology.